Raymond James & Associates reduced its position in shares of Waters Co. (NYSE:WAT) by 9.8% in the second quarter, HoldingsChannel.com reports. The firm owned 73,004 shares of the medical instruments supplier’s stock after selling 7,960 shares during the quarter. Raymond James & Associates’ holdings in Waters were worth $14,133,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. Laurion Capital Management LP lifted its position in shares of Waters by 441.3% during the 2nd quarter. Laurion Capital Management LP now owns 23,992 shares of the medical instruments supplier’s stock valued at $4,645,000 after buying an additional 19,560 shares in the last quarter. Rampart Investment Management Company LLC lifted its position in shares of Waters by 43.7% during the 2nd quarter. Rampart Investment Management Company LLC now owns 8,003 shares of the medical instruments supplier’s stock valued at $1,549,000 after buying an additional 2,433 shares in the last quarter. OppenheimerFunds Inc. lifted its position in shares of Waters by 69.8% during the 2nd quarter. OppenheimerFunds Inc. now owns 1,977 shares of the medical instruments supplier’s stock valued at $383,000 after buying an additional 813 shares in the last quarter. Caisse DE Depot ET Placement DU Quebec lifted its position in shares of Waters by 62.3% during the 2nd quarter. Caisse DE Depot ET Placement DU Quebec now owns 3,675 shares of the medical instruments supplier’s stock valued at $711,000 after buying an additional 1,410 shares in the last quarter. Finally, Burney Co. lifted its position in shares of Waters by 3.0% during the 2nd quarter. Burney Co. now owns 53,305 shares of the medical instruments supplier’s stock valued at $10,319,000 after buying an additional 1,576 shares in the last quarter. Institutional investors and hedge funds own 99.27% of the company’s stock.

WAT has been the topic of a number of analyst reports. Cleveland Research cut Waters from a “neutral” rating to an “underperform” rating in a research report on Thursday, June 14th. Zacks Investment Research raised Waters from a “hold” rating to a “buy” rating and set a $215.00 price objective on the stock in a research report on Saturday, June 30th. Morgan Stanley lifted their price objective on Waters from $200.00 to $205.00 and gave the company an “equal weight” rating in a research report on Friday, July 13th. Bank of America cut Waters from a “neutral” rating to an “underperform” rating and set a $190.00 price objective on the stock. in a research report on Monday, July 16th. Finally, Janney Montgomery Scott cut Waters from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $230.00 to $211.00 in a research report on Tuesday, July 17th. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating and four have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $206.27.

Shares of WAT opened at $195.09 on Tuesday. The company has a market cap of $15.12 billion, a PE ratio of 26.05, a PEG ratio of 2.40 and a beta of 0.96. Waters Co. has a 1 year low of $177.58 and a 1 year high of $220.20. The company has a debt-to-equity ratio of 0.58, a quick ratio of 5.95 and a current ratio of 6.58.

Waters (NYSE:WAT) last released its earnings results on Tuesday, July 24th. The medical instruments supplier reported $1.95 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.92 by $0.03. The firm had revenue of $596.20 million for the quarter, compared to the consensus estimate of $598.73 million. Waters had a return on equity of 27.85% and a net margin of 2.12%. The company’s revenue for the quarter was up 6.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.76 EPS. equities analysts forecast that Waters Co. will post 8.11 EPS for the current fiscal year.

In other news, SVP Elizabeth B. Rae sold 4,000 shares of the business’s stock in a transaction that occurred on Monday, August 27th. The stock was sold at an average price of $190.62, for a total transaction of $762,480.00. Following the transaction, the senior vice president now owns 9,443 shares of the company’s stock, valued at approximately $1,800,024.66. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 0.98% of the company’s stock.

About Waters

Waters Corporation, a specialty measurement company, provides analytical workflow solutions in the United States, Europe, Asia, and internationally. It designs, manufactures, sells, and services high and ultra performance liquid chromatography technology, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans.

Featured Story: Earnings Per Share

Want to see what other hedge funds are holding WAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Waters Co. (NYSE:WAT).

Institutional Ownership by Quarter for Waters (NYSE:WAT)

Receive News & Ratings for Waters Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Waters and related companies with MarketBeat.com's FREE daily email newsletter.